Pregabalin Versus Dexmedetomidine for Delirium Prevention After Cardiac Surgery
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 60 people enrolled
- Started
- 15 Dec 2022
- Ended
- 2 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pregabalin
- Dexmedetomidine
- Record updated
- 7 January 2025
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III scheduled for cardiac surgery
Who cannot take part
- Patients who had history of psychiatric diseases; inability to communicate; previous history of POD; preoperative sick sinus syndrome
- Previous cardiac or thoracic surgery
- Allergy/sensitivity to pregabalin or dexmedetomidine
- Severe bradycardia (heart rate <50 beat per minute)
- Severe hepatic or renal insufficiency
- Known diagnosis of depression or other major psychiatric diseases
- Cognitive impairment or inability to cooperate with the study
- Renal insufficiency, and history of substance abuse
- Second-degree or above atrioventricular block without pacemaker
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to compare the effect of perioperative administration of pregabalin versus dexmedetomidine on the prevalence and lasting duration of delirium in elderly patients after cardiac surgery.
The 2 groups in the trial
- pregabalin groupExisting treatment, for comparison
patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 h for 24h postoperatively by nasogastric tube or orally. Patients will receive IV saline as placebo with the same rate of dexmedetomidine.
Treatment: Pregabalin
- dexmedetomidine groupExisting treatment, for comparison
patients in the dexmedetomidine group will receive after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h. Patients will receive placebo 2 h prior to induction of anesthesia and every 12 h for 24h postoperatively by nasogastric tube or orally. If patients are hemodynamically unstable, the bolus dose will be omitted. The infusion of dexmedetomidine will be continued for a maximum period of 24 h. Dexmedetomidine infusion will be not discontinued before extubation.
Treatment: Dexmedetomidine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pregabalin Versus Dexmedetomidine for Delirium Prevention After Cardiac Surgery: A Randomized Double-Blind Trial
- Record updated
- 7 January 2025